These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38781501)

  • 1. Aniquinazoline B, a Fungal Natural Product, Activates the μ-Opioid Receptor.
    Damiescu R; Elbadawi M; Dawood M; Klauck SM; Bringmann G; Efferth T
    ChemMedChem; 2024 May; ():e202400213. PubMed ID: 38781501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of pyrazole-1-carboxamide derivatives as novel Gi-biased μ-opioid receptor agonists.
    Jung JH; Jang IH; Kim YO; Kim S; Yoon MH; Kim YC
    Drug Dev Res; 2022 Nov; 83(7):1600-1612. PubMed ID: 36124859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Label-free cell phenotypic study of opioid receptors and discovery of novel mu opioid ligands from natural products.
    Hou T; Xu F; Peng X; Zhou H; Zhang X; Qiu M; Wang J; Liu Y; Liang X
    J Ethnopharmacol; 2021 Apr; 270():113872. PubMed ID: 33485984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic Understanding of Peptide Analogues, DALDA, [Dmt
    Dumitrascuta M; Bermudez M; Ballet S; Wolber G; Spetea M
    Molecules; 2020 Apr; 25(9):. PubMed ID: 32365707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potentially biased agonists of mu-opioid receptor (MOR) through molecular docking, pharmacophore modeling, and MD simulation.
    Jiang X; Li S; Zhang H; Wang LL
    Comput Biol Chem; 2021 Feb; 90():107405. PubMed ID: 33184004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characteristics of the naked mole rat μ-opioid receptor.
    Busch-Dienstfertig M; Roth CA; Stein C
    PLoS One; 2013; 8(11):e79121. PubMed ID: 24312175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a Potent Highly Biased MOR Partial Agonist among Diastereomeric C9-Hydroxyalkyl-5-phenylmorphans.
    Lutz JA; Sulima A; Gutman ES; Bow EW; Luo D; Kaska S; Prisinzano TE; Paronis CA; Bergman J; Imler GH; Kerr AT; Jacobson AE; Rice KC
    Molecules; 2023 Jun; 28(12):. PubMed ID: 37375350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform.
    Vasudevan L; Vandeputte M; Deventer M; Wouters E; Cannaert A; Stove CP
    Biochem Pharmacol; 2020 Jul; 177():113910. PubMed ID: 32179045
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Santos EJ; Akbarali HI; Bow EW; Chambers DR; Gutman ES; Jacobson AE; Kang M; Lee YK; Lutz JA; Rice KC; Sulima A; Negus SS
    J Pharmacol Exp Ther; 2024 Apr; ():. PubMed ID: 38637015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand-Free Signaling of G-Protein-Coupled Receptors: Relevance to μ Opioid Receptors in Analgesia and Addiction.
    Sadee W; McKew JC
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro functional assays as a tool to study new synthetic opioids at the μ-opioid receptor: Potential, pitfalls and progress.
    Vandeputte MM; Vasudevan L; Stove CP
    Pharmacol Ther; 2022 Jul; 235():108161. PubMed ID: 35183593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of G protein-biased agonists of μ-opioid receptor on addiction-related behaviors.
    Kudla L; Przewlocki R
    Pharmacol Rep; 2021 Aug; 73(4):1033-1051. PubMed ID: 33835467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation.
    Groer CE; Schmid CL; Jaeger AM; Bohn LM
    J Biol Chem; 2011 Sep; 286(36):31731-41. PubMed ID: 21757712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators.
    Kruegel AC; Gassaway MM; Kapoor A; Váradi A; Majumdar S; Filizola M; Javitch JA; Sames D
    J Am Chem Soc; 2016 Jun; 138(21):6754-64. PubMed ID: 27192616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residues W320 and Y328 within the binding site of the μ-opioid receptor influence opiate ligand bias.
    Hothersall JD; Torella R; Humphreys S; Hooley M; Brown A; McMurray G; Nickolls SA
    Neuropharmacology; 2017 May; 118():46-58. PubMed ID: 28283391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation.
    Coluzzi F; Rullo L; Scerpa MS; Losapio LM; Rocco M; Billeci D; Candeletti S; Romualdi P
    CNS Drugs; 2022 Jun; 36(6):617-632. PubMed ID: 35616826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the μ- and κ-opioid receptor activation by eight new synthetic opioids using the [
    Otte L; Wilde M; Auwärter V; Grafinger KE
    Drug Test Anal; 2022 Jul; 14(7):1187-1199. PubMed ID: 35142070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of plant-derived alkaloids, corydine and corydaline, as novel mu opioid receptor agonists.
    Kaserer T; Steinacher T; Kainhofer R; Erli F; Sturm S; Waltenberger B; Schuster D; Spetea M
    Sci Rep; 2020 Aug; 10(1):13804. PubMed ID: 32796875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dilemma of Addiction and Respiratory Depression in the Treatment of Pain: A Prototypical Endomorphin as a New Approach.
    Webster L; Schmidt WK
    Pain Med; 2020 May; 21(5):992-1004. PubMed ID: 31165885
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.